Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 2Peritoneal Neoplasms 1

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5liposomal doxorubicin 4Topotecan 3Cyclophosphamide 3pembrolizumab 2oregovomab 2olaparib 2niraparib 2fludarabine 2Nivolumab 2Drug Therapy 2trastuzumab deruxtecan 1rucaparib 1ribociclib 1palbociclib 1mirvetuximab soravtansine 1isoquercitrin 1irinotecan sucrosofate 1fludarabine phosphate 1denileukin diftitox 1anlotinib 1Tinzaparin 1Saline Solution 1Propranolol 1Preoperative Exercise 1Platinum 1Palliative Care 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × oregovomab × 90 days × Clear all
NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

CanariaBio Inc.

Phase 2 Active not recruiting
10 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04498117 2026-04-01

FLORA-5

CanariaBio Inc.

Phase 3 Active not recruiting
615 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡